In the molecular docking model, the structure of mangiferin showed a high binding potential with TNF-α and MMP-9 and a reduced colonic injury partly through attenuating the activity of TNF-α and MMP-9 in the colitis model [98]. This evidence concerns the gene MMP9 and colitis.